FOIA: OHRP Investigation – Brigham and Woment’s Hospital
FOIA: OHRP Investigation – Brigham and Women’s Hospital
Letter page one:
Letter page 2:
Letter page 3:
Similar Posts
DHHS Reverses its Legal Position Petitioning FOR Whistleblower Protection for Dr. Fishbein
DHHS Reverses its Legal Position Petitioning FOR Federal Whistleblower Protection for Dr. Fishbein Thu, 3 Feb 2005 The Washington Post reports: “Department of Health and Human Services filed a legal petition this week in support of an employee the department is trying to fire. HHS told the Merit Systems Protection…
Government Investigations, 1990 – 2001
Government Investigations 1990 to August 2001 National Bioethics Advisory Committee Report: ETHICAL AND POLICY ISSUES IN RESEARCH INVOLVING HUMAN PARTICIPANTS, 1998 Exhibit 3.1: Office of Protection from Research Risks (OPRR) Compliance Oversight Investigations Resulting in Restrictions/Actions to Institutions that have Multiple Project Asssurances (MPA) between January 1990 – June 2000…
Acting FDA Head Temporarily Drops NCI Duty – WashPost
Acting FDA Head Temporarily Drops NCI Duty – WashPost Sat, 1 Oct 2005 Who is kidding who? The appointment of a long time Bush friend, Dr. Andrew Eschenbach, head of the National Cancer Institue, as acting commissioner of the Food and Drug Adminsitration reeks of conflicts of interest–not just one…
Natrecor found to worsen kidney function, hasten death – NYT
Natrecor found to worsen kidney function, hasten death – NYT Tue, 17 May 2005 Natrecor, a drug approved by the FDA for treating patients with heart failure, is being widely prescribed off label for unapproved uses. The drug is prescribed for so-called “tune-ups” in outpatient clinics – although that use…
2 to 5 year old children targeted for Smallpox Vaccine trial_DHHS
2 to 5 year old children targeted for Smallpox Vaccine trial_DHHS Sat, 2 Nov 2002 An announcement in the Federal Register, Oct 31, 2002, by the Office of Public Health and Science and Food and Drug Administration calls for public review and comment about proposals to the Secretary of Health…
BioMedNet: FDA Divorces Chemistry from Biology
Subject: BioMedNet: FDA Divorces Chemistry from Biology Date: Sun, 15 Sep 2002 10:25:07 -0400 FDA maintains two administrative oversight branches for medical products: Center for Biologics Evaluation and Research (CBER)–is responsible for overseeing the safety of bio-tech based therapies, vaccines, blood safety, and gene therapy. Center for Drug Evaluation and…